前列地尔联合奥拉西坦治疗急性脑梗死的临床疗效

Clinical effects of alprostadil combined with oxiracetam on acute cerebral infarction

目的探讨前列地尔联合奥拉西坦治疗急性脑梗死的疗效及安全性。方法选取80例急性脑梗死患者,随机分为对照组和治疗组,在常规治疗的基础上,对照组给予前列地尔注射液治疗,治疗组在对照组的基础上加用奥拉西坦注射液治疗,两组均连续治疗2 w,观察两组治疗前后美国国立卫生研究院卒中量表(NIHSS)及巴塞尔(Barthel)指数评分结果、血清中CRP的浓度及安全性。结果治疗后,治疗组NIHSS评分明显低于对照组(P<0.05);Barthel评分明显高于对照组(P<0.05);治疗7 d、14 d后,治疗组血清CRP浓度明显低于对于对照组(P<0.05);两组均未出现严重不良反应。结论在常规治疗的基础上,采用前列地尔联合奥拉西坦治疗急性脑梗死,可显著提高患者的生活自理能力,降低血清中CRP的浓度,提高临床治疗的效果,且安全、可靠,具有较大的临床借鉴意义。

Objective To investigate the clinical effects and safety of alprostadil combined with oxiracetam in treatment of acute cerebral infarction. Methods Total 80 patients with acute cerebral infarction were selected and divided randomly into the treatment group and the control group. On the basis of conventional therapy,the control group was provided with alprostadil injection treatment and the treatment group was provided with oxiracetam injection treatment in addition to alprostadil injection. Both groups were treated for two weeks;and then,America National Institute of Health Stroke Scale（ NIHSS）and Barthel index score,concentration of serum CRP before and after the treatment were observed. Results After treatment,NIHSS score of the treatment group was significantly lower than that of the control group（P〈0. 05）;the Barthel index score of the treatment group was significantly higher than that of the control group（P 〈0. 05）. After seven days and fourteen days of treatment,serum CRP concentration of the treatment group was significantly lower than that of the control group（P〈0. 05）at the same time. Both groups had no serious adverse reaction. Conclusion On the basis of conventional therapy,alprostadil combined with oxiracetam in treatment of acute cerebral infarction can significantly improve the patientˊs self-care ability,lower the serum concentration of CRP,improve the clinical effect,and the combined treatment is safe and reliable,having great clinical significance.